Keros Therapeutics Presented Additional Data From Its Two Ongoing Phase 2 Trials Of Elritercept (KER-050), For Very Low-, Low-, Or Intermediate-Risk Myelodysplastic Syndromes And Myelofibrosis
Keros Therapeutics Presented Additional Data From Its Two Ongoing Phase 2 Trials Of Elritercept (KER-050), For Very Low-, Low-, Or Intermediate-Risk Myelodysplastic Syndromes And Myelofibrosis
keros therapeutics给出了Elritercept（KER-050）用于非常低危、低危或中度危险的骨髓增生异常综合症和骨髓纤维化的两项进行中的2期试验的补充数据。
- Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden.
- Durable clinical responses were associated with improvements in patient-reported measures of fatigue.
- Data from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can not only ameliorate ineffective hematopoiesis and address cytopenias, but also provide broader clinical benefit, as supported by observed reductions in spleen volume and improved total symptom scores.
- 在低风险骨髓增生异常综合症中，Elritercept持续展现出耐用的输注独立性，包括高输注负担的患者。
- 耐用的临床反应与疲劳的患者报告指标的改善相关。
- 来自骨髓纤维化正在进行的II期临床试验的数据始终表明，Elritercept不仅可以改善无效造血和处理细胞减少症，还能提供更广泛的临床益处，如观察到的脾脏体积减小和改善的总症状评分所支持。